We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




AI-Based Method Shows Promise for Pathological Diagnosis of Hereditary Kidney Diseases

By LabMedica International staff writers
Posted on 01 Nov 2024

Alport syndrome is a hereditary kidney disorder characterized by kidney dysfunction, sensorineural hearing loss, and ocular abnormalities. More...

Early in the disease, patients experience hematuria, which is followed by proteinuria and, eventually, end-stage renal failure that necessitates renal replacement therapies such as dialysis or kidney transplantation. The exact prevalence of Alport syndrome remains uncertain; however, the X-linked form, caused by a mutation in a gene located on the X chromosome, is the most prevalent type. Males, who possess a single X chromosome (XY), tend to experience more severe symptoms compared to females, who have two X chromosomes (XX). Although female patients with X-linked Alport syndrome are often thought to have a milder variant of the disease, studies conducted in the United States and Japan indicate that about 15% of these women may reach end-stage renal failure by age 40. Diagnosing Alport syndrome typically involves genetic testing and a pathological examination of kidney tissue. However, accurately predicting renal outcomes in female patients presents challenges, underscoring the need for indicators that can evaluate the effectiveness of renal protective treatments, such as antihypertensive medications, which have shown potential to improve patient prognosis.

A research team at the University of Tsukuba (Tsukuba, Japan) has developed an innovative imaging technique to visualize lesions in the glomerular basement membrane using a mouse model of Alport syndrome. By applying deep learning methodologies to pathological image data, the researchers achieved automated detection of lesions through artificial intelligence (AI). The study utilized a mouse model that simulates Alport syndrome to compare the kidney lesions between male and female subjects, aiming to provide insights into the specifics of these lesions in females. They created a modified periodic acid methenamine silver stain to observe basement membrane lesions in areas where type IV collagen α5 is intact as well as in regions where it is absent, which are distinctive in female patients.

Additionally, the AI system was able to automatically identify these lesions using deep learning techniques, as detailed in research published in the American Journal of Pathology. The quantitative measurements of kidney lesions in female mice, as assessed by the imaging AI software, showed a positive correlation with proteinuria levels, suggesting that this approach may assist in predicting kidney function outcomes in women with Alport syndrome.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Automated Urinalysis Solution
UN-9000
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.